ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,149.27
0.79%
Dow Jones
43,905.23
1.14%
Gold vs US Dollar
2,669.74
0.65%
Brent Oil
73.945
1.52%
Bitcoin
98,249.71
4.12%
Pepperstone
Advertisement
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Europe
  5. EU

  6. Ipsen SA (IPN) Share Price

IPN Ipsen SA

107.60
0.20 (0.19%)
21 Nov 2024 - Closed
Delayed by 15 minutes
 Name  Symbol  Market  Type  ISIN  Description 
 Ipsen SA EU:IPN Euronext Ordinary Share FR0010259150 
     Change  % Chg  Cur  Bid  Offer  High  Low  Open  Volume  Chg Time
Upgrade Icon
 		 RN  NRN 
   0.20 0.19 107.60 107.40 108.30 108.20 107.00 107.7 46,561 16:40:00   
 Type  Size  Price  Time  Units 
  30 107.60 16:35:16 EUR
 
Recent News
DateTimeSource
HeadlineMore IPN News
18/11/202406:00UKREGBylvay® (odévixibat) montre une amélioration soutenue en termes de sévérité des démangeaisons et de taux d’acides biliaires sériques chez les patients atteints de CIFP et du SAG
18/11/202406:00GLOBEBylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS
18/11/202406:00UKREGBylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS
15/11/202416:00GLOBEIqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus
15/11/202416:00UKREGIqirvo® (elafibranor) montre des données d’efficacité et de tolérance sur une période allant jusqu’à trois ans chez les patients atteints de CBP avec une amélioration de la fatigue et du prurit
15/11/202416:00UKREGIqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus
07/11/202417:00UKREGIpsen - October 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital
Period
Draw mode
Data Downloads for IPN

Export historical price information open, high, low, close, volume (OHLCV) to Excel

Intraday price data (2 weeks, 1 minute bars)


Loading Follow Feed...

Latest Ipsen SA Articles

BLACK FRIDAY

ADVFN

Celebrating 25 years Est 1999-2024

Save up to 60%* for Level 2 Lite

1 year 40%, 2 years 50% and *3 years 60%
EU Flag

*Across 3 years £2132.64 only £853.06